徐岩, 王广树, 孙薇, 杨晓虹, 徐利保. 小分子IGF-1R抑制剂的研究进展J. 药学学报, 2008, 43(10): 979-984.
引用本文: 徐岩, 王广树, 孙薇, 杨晓虹, 徐利保. 小分子IGF-1R抑制剂的研究进展J. 药学学报, 2008, 43(10): 979-984.
shu
XU Yan, WANG Guang-shu, SUN Wei, YANG Xiao-hong, XU Li-bao. Progress in the studies on small molecule IGF-1R inhibitorsJ. Acta Pharmaceutica Sinica, 2008, 43(10): 979-984.
Citation: XU Yan, WANG Guang-shu, SUN Wei, YANG Xiao-hong, XU Li-bao. Progress in the studies on small molecule IGF-1R inhibitorsJ. Acta Pharmaceutica Sinica, 2008, 43(10): 979-984.
shu

小分子IGF-1R抑制剂的研究进展

Progress in the studies on small molecule IGF-1R inhibitors

    摘要
  • 摘要: 胰岛素样生长因子1受体(IGF-1R)的信号转导途径与肿瘤的发生密切相关。抑制IGF-1R的活性，可以有效控制肿瘤细胞的生长和转移，并增强肿瘤对化疗、放疗的敏感性。以IGF-1R为靶标的治疗方法中，IGF-1R单克隆抗体和小分子激酶抑制剂已进入临床试验阶段。本文对近年来以IGF-1R为靶点的小分子激酶抑制剂的研究进展进行综述。

     

    Abstract: The importance of insulin-like growth factor 1 receptor (IGF-1R) signaling in malignant behaviour of tumour cells is well established. Inhibiting the activity of IGF-1R may result in striking apoptosis in malignant cells growing. IGF-1R antibodies which are currently in phase I and II clinical trials and several IGF-1R TKIs have preclinically been characterized. This review describes recent developments of small molecule tyrosine kinase inhibitors.

     

    • HTML全文
    • 参考文献(0)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回